Semaglutide Clinical Trials: Results & How to Enroll
Complete guide to Semaglutide clinical trial history, published results, and current research status.
Clinical Trial History
Semaglutide 2.4mg produced 14.9% mean weight loss vs 2.4% for placebo over 68 weeks.
Semaglutide reduced major cardiovascular events (MACE) by 20% vs placebo in patients with established cardiovascular disease — a landmark finding leading to expanded use.
Frequently Asked Questions
What clinical trials have studied Semaglutide?
Semaglutide has been studied in multiple clinical trials. The key findings are documented in the clinical research section of this guide. Refer to ClinicalTrials.gov for complete trial records and enrollment information.
Is Semaglutide still in clinical trials?
FDA approved for T2D (Ozempic, 2017), obesity (Wegovy, 2021), CV risk reduction (2023), oral T2D (Rybelsus, 2019). For current trial status, search ClinicalTrials.gov using the drug name "Semaglutide".
References & Sources
- [1]Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
- [2]Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- [3]FDA — Semaglutide (Wegovy) Approval and Drug Label
- [4]PubMed search: semaglutide obesity clinical trials
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.